Evolus Strategic Advantage and Growth

LOVEVOLUS ESTIMATED GLOBAL AVERAGE ADOPTION RATE* (ANNUAL INCOME $50K+) De AGE 20-40 % CURRENTLY USING NEUROMODULATORS % INTEND TO USE NEUROMODULATORS IN THE NEXT 5 YEARS 16% 15% 15% PROJECTED ADOPTION AMONG THE YOUNGER DEMOGRAPHIC: 2X AS LIKELY AS THE OLDER DEMOGRAPHIC 20-30 31-40 41+ 10.5% 41-50 10.5% 51-60 4.5% 60+ 4% 2% 11.5% 9% * From Extreme to Mainstream: The Future of Aesthetics Injectables. McKinsey & Company, Dec. 2021 16% 20-40 YEAR OLDS INTEND TO USE NEUROMODULATORS IN NEXT 5 YRS 8% 41+ YEAR OLDS INTEND TO USE NEUROMODULATORS IN NEXT 5 YRS 14

View entire presentation